Provention Bio is focused on developing and commercializing novel therapeutics to address unmet medical needs in autoimmune diseases. Their approach utilizes targeted biologics to modulate immune responses, aiming to improve patient outcomes and reduce disease progression.
Funding
$329M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many autoimmune diseases lack targeted therapies, leading to broad immunosuppression and suboptimal patient outcomes. Current treatments often fail to address the underlying cause of the disease, resulting in disease progression and significant morbidity.
Solution
Sanofi is developing targeted biologics to modulate immune responses and address the unmet medical needs in autoimmune diseases. Their approach focuses on precision medicine, aiming to develop therapies that selectively target the specific immune pathways driving disease pathology. By modulating the immune system in a targeted manner, Sanofi hopes to improve patient outcomes, reduce disease progression, and minimize off-target effects associated with traditional immunosuppressants. The company is committed to advancing conversations and developing better patient-centric treatments and care solutions.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases and the healthcare professionals who treat them, including rheumatologists, immunologists, and other specialists.
Features
- Targeted biologics designed to modulate specific immune pathways
- Focus on precision medicine for autoimmune disease treatment
- Development of therapies aimed at reducing disease progression
- Patient-centric approach to treatment and care solutions